COVID-19 Alters But Doesn’t Change M&A Machine In 2020

$12bn Viatris Merger Completes In Remarkable Year

Mergers and acquisitions have long been a tool for value creation in the generics and biosimilars space. Even with the entire life sciences sector overwhelmed by the novel coronavirus pandemic, deals big and small continued in 2020.

MnA
Billions of dollars were once again spent on generic and biosimilar M&A in 2020 • Source: Shutterstock

More from Deals

More from Business